Meeting Banner
Abstract #4787

Validation of SSIFT MRI: Differentiation between brain tumor and radiation necrosis

Sean P Devan1,2, Xiaoyu Jiang1,3, Guozhen Luo4, Jing Cui1, Jingping Xie1, Zhongliang Zu1,3, Joel R Garbow5,6, James D Quirk5, John A Engelbach5, Austin N Kirschner4, John C Gore1,3, and Junzhong Xu1,3
1Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN, United States, 2Chemical and Physical Biology Program, Vanderbilt University, Nashville, TN, United States, 3Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, United States, 4Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN, United States, 5Mallinckrodt Institute of Radiology, Washington University, St. Louis, MO, United States, 6Alvin J Siteman Cancer Center, Washington University, St. Louis, MO, United States

SSIFT is a recently developed MRI method that provides a specific means to detect brain tumors based on their differences in cell size. However, to date SSIFT has not been adequately validated. We therefore used computer simulations and studies of cultured cells in vitro and animal models in vivo to comprehensively validate SSIFT for brain cancer imaging. The results suggest SSIFT is highly specific for cell size and can differentiate brain tumors from other brain abnormalities such as peri-tumor edema and radiation necrosis, which cannot be reliably distinguished by other current MRI methods.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here